No quarterly revenue total was found in Biohaven Ltd.'s SEC filings.
Biohaven Ltd. (BHVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$107.0 million. As of Sep 30, 2026 it held $161.1 million in cash and investments and $36.1 million in total debt.
Revenue
—
Net income
$-129.28M
+25.5% vs year-ago quarter
Operating cash flow
$-106.85M
+26.7% vs year-ago quarter
Free cash flow
$-107.03M
+26.6% vs year-ago quarter
EPS
$-0.86
+47.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
151.06M
+42.7% vs year-ago quarter
Net cash
$124.97M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHVN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- New Haven, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1935979
- Former names
- Biohaven Research Ltd. (until Sep 14, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$126.4M | -$124.9M | -$130.4M | -$142.7M | -$169.4M |
| Net income | -$129.3M | -$137.3M | -$130.5M | -$145.6M | -$173.4M |
| Diluted EPS | -$0.86 | -$0.91 | -$0.88 | -$1.21 | -$1.64 |
| Operating cash flow | -$106.9M | -$85.1M | -$149.9M | -$130.7M | -$145.7M |
| Free cash flow | -$107.0M | -$85.6M | -$149.9M | -$130.7M | -$145.7M |
| Total assets | $263.7M | $370.7M | $466.4M | $451.4M | $409.1M |
| Total liabilities | $361.9M | $358.5M | $336.9M | $399.4M | $426.3M |
| Stockholders' equity | -$98.2M | $12.2M | $129.5M | $52.1M | -$17.2M |
| Cash and investments | $161.1M | $267.9M | $347.8M | $319.1M | $260.2M |
| Total debt | $36.1M | $37.6M | $44.3M | $45.7M | $45.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 15, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 26, 2026 | Aug 26, 2026 |
All 282 Biohaven Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.